|
Epoprostenol (also known as Prostacycin or Prostaglandin I2 (PGI2))
|
| bet | 189/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Epoprostenol (also known as Prostacycin or Prostaglandin I2 (PGI2))
Revision Date : 27/04/2021
|
Approved : TCO, KOH
|
Indication :
|
Persistent pulmonary hypertension of the newborn unresponsive to usual ventilatory strategies, inhaled nitric oxide and appropriate inotropic support.
|
Dose :
|
Initial dose 2nanograms/kg/minute
Titrate to clinical effect increasing by 1-2nanogram/kg/min not faster than every 15 minutes.
Limited evidence for max dose for PPHN in neonates (UK guidance (BNF/NICE) state usual max 20nanograms/kg/min; rarely up to 40nanograms/kg/min)
Doses up to 80-150nanograms/kg/min used in adult and paediatric patients for chronic pulmonary arterial hypertension
|
Interval :
|
Continuous infusion only
|
Route :
|
I.V. (central venous line strongly recommended)
|
Total Daily Dose :
|
|
Comments :
|
|
|
| |
